Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Istanbul - Delayed Quote TRY

Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi (GENIL.IS)

121.30
+1.30
+(1.08%)
At close: April 25 at 6:09:51 PM GMT+3
Currency in TRY All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
14,740,692.70
14,740,692.70
11,769,208.45
10,639,338.95
2,501,352.84
Cost of Revenue
11,891,721.25
11,891,721.25
9,171,181.97
8,727,891.79
2,044,993.56
Gross Profit
2,848,971.46
2,848,971.46
2,598,026.48
1,911,447.16
456,359.27
Operating Expense
1,676,013.44
1,676,013.44
1,699,037.63
655,574.13
184,015.83
Operating Income
1,172,958.02
1,172,958.02
898,988.85
1,255,873.03
272,343.44
Net Non Operating Interest Income Expense
-344,494.07
-344,494.07
-192,325.79
140,670.72
-95,181.82
Pretax Income
420,627.88
420,627.88
378,803.99
501,115.68
301,438.19
Tax Provision
277,070.16
277,070.16
-274,340.29
-139,501.41
-8,928.49
Net Income Common Stockholders
148,676.81
148,676.81
656,320.21
639,952.05
310,845.37
Diluted NI Available to Com Stockholders
148,676.81
148,676.81
656,320.21
639,952.05
310,845.37
Basic EPS
0.50
--
2.19
2.14
1.34
Diluted EPS
0.50
--
2.19
2.14
1.34
Basic Average Shares
300,000
--
300,000
300,000
300,000
Diluted Average Shares
300,000
--
300,000
300,000
300,000
Total Operating Income as Reported
1,091,391.44
1,091,391.44
649,582.40
1,120,988.53
202,081.32
Rent Expense Supplemental
--
--
--
4,499.88
3,031.52
Total Expenses
13,567,734.68
13,567,734.68
10,870,219.60
9,383,465.92
2,229,009.40
Net Income from Continuing & Discontinued Operation
148,676.81
148,676.81
656,320.21
639,952.05
310,845.37
Normalized Income
178,593.69
178,593.69
648,965.51
644,195.61
326,043.85
Interest Income
356,382.91
356,382.91
248,743.96
192,423.20
38,235.86
Interest Expense
684,042.50
684,042.50
403,520.19
47,111.58
132,452.48
Net Interest Income
-344,494.07
-344,494.07
-192,325.79
140,670.72
-95,181.82
EBIT
1,104,670.37
1,104,670.37
782,324.19
548,227.25
433,890.67
EBITDA
1,473,114.73
1,473,114.73
1,166,324.76
740,308.20
477,728.19
Reconciled Cost of Revenue
11,891,721.25
11,891,721.25
9,171,181.97
8,727,891.79
2,044,993.56
Reconciled Depreciation
368,444.36
368,444.36
384,000.57
192,080.95
43,837.53
Net Income from Continuing Operation Net Minority Interest
148,676.81
148,676.81
656,320.21
639,952.05
310,845.37
Total Unusual Items Excluding Goodwill
-39,889.18
-39,889.18
9,806.26
-5,511.12
-18,998.10
Total Unusual Items
-39,889.18
-39,889.18
9,806.26
-5,511.12
-18,998.10
Normalized EBITDA
1,513,003.91
1,513,003.91
1,156,518.50
745,819.32
496,726.29
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-9,972.30
-9,972.30
2,451.57
-1,267.56
-3,799.62
12/31/2021 - 8/5/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

AEQ.F Aequus Pharmaceuticals Inc.
0.0005
0.00%
 
5SS0.F Simply Better Brands Corp.
0.5340
+3.49%
 
GABA.ST Gabather AB (publ)
0.0396
-2.94%
 
VCBD Vitalibis, Inc.
0.0018
+28.57%
 
KLAR.ST Klaria Pharma Holding AB (publ.)
1.1500
-3.77%
 
STX.L Shield Therapeutics plc
2.3500
+3.98%
 
CRNO-B.ST Cereno Scientific AB (publ)
8.00
+0.38%
 
CPIX Cumberland Pharmaceuticals Inc.
4.9700
+2.58%
 
BCRX BioCryst Pharmaceuticals, Inc.
8.39
+2.07%